Key Performance
More- Earnings Score: N/A
- Momentum Score: 61
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, that rejected the company's bitopertin drug application due to insufficient evidence. The rejection caused Disc Medicine's stock to plummet 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
06/21/2026, 1:09 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. The firm is preparing a class action lawsuit to recover investor losses.
06/18/2026, 11:41 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), TruBridge (TBRG), and PennyMac Financial Services (PFSI) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% on February 13, 2026, following an FDA Complete Response Letter rejecting its bitopertin program NDA. Investors who suffered losses are encouraged to join prospective class action lawsuits.
06/15/2026, 7:25 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against multiple companies. Disc Medicine (IRON) received an FDA Complete Response Letter on its bitopertin program, causing a 22% stock price decline on February 13, 2026. The firm is also pursuing class action lawsuits against DNOW Inc. and Badger Meter, Inc. on behalf of affected shareholders.
06/12/2026, 3:54 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), TruBridge (TBRG), and Graphic Packaging Holding Company (GPK) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% following an FDA Complete Response Letter on its bitopertin program in February 2026.
06/09/2026, 9:54 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and the firm is preparing a class action lawsuit to recover investor losses.
06/05/2026, 3:25 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) following the FDA's rejection of the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused the stock to plummet 22%. Investors who suffered losses are encouraged to join a class action lawsuit.
06/02/2026, 10:38 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. The firm is preparing a class action lawsuit to recover investor losses.
05/25/2026, 9:41 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter rejecting the company's bitopertin drug application on February 13, 2026. The rejection, citing uncertainties requiring additional evidence, caused Disc Medicine's stock to plummet 22%. The firm is preparing a class action lawsuit to recover investor losses.
05/19/2026, 10:31 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, stating it could not approve the company's bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. The firm is preparing a class action lawsuit to recover investor losses.
05/13/2026, 7:32 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, stating it could not approve the company's bitopertin drug application due to uncertainties requiring additional evidence. The news triggered a 22% stock price decline. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
05/10/2026, 8:33 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine (IRON), Immutep Ltd. (IMMP), and New Era Energy & Digital, Inc. (NUAI) for allegedly issuing materially misleading business information. Disc Medicine's stock fell 22% following an FDA Complete Response Letter on its bitopertin program on February 13, 2026. The firm is preparing class action lawsuits seeking recovery of investor losses.
05/04/2026, 8:15 PM • GlobeNewswire
Rosen Law Firm is soliciting investors who suffered losses in ODDITY Tech Ltd., Pinterest, Inc., and Disc Medicine, Inc. to join securities class action lawsuits. The firm alleges that ODDITY Tech made false statements about its business performance due to an algorithm change by its largest advertising partner that increased customer acquisition costs. Lead plaintiff deadlines and contingency fee arrangements are available for eligible investors.
04/25/2026, 3:10 PM • GlobeNewswire
The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.
04/22/2026, 1:00 PM • GlobeNewswire
Disc Medicine will present Phase 2 RALLY-MF trial data for DISC-0974, an anti-hemojuvelin antibody for treating anemia in myelofibrosis, at the ASCO Annual Meeting on June 2, 2026. The company reported that initial data showed unprecedented anemia response rates in this hard-to-treat patient population, with additional patient data to be presented at the conference.
04/21/2026, 10:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.